← Back to Search

CaRE-4-alloBMT plus usual care group for Allogeneic Transplantation

N/A

Waitlist Available

Led By Jennifer M Jones, PhD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Awaiting alloBMT

Able to communicate in English

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial is testing the feasibility and safety of an innovative rehabilitation intervention for patients undergoing allogeneic bone marrow transplantation (alloBMT). The goal is to improve physical function, disability, nutritional status, distress, quality of life, healthcare utilization, and survival.

Eligible Conditions

Allogeneic Transplantation
Blood Cancers
Cancer Rehabilitation

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Drop-out rates as a measure of feasibility

Measuring safety as assessed during one-on-one interviews with health coach - this wll be (analyzed as qualitative data) done over MS Teams and will be a conversational question and answer format.

Patient preference as assessed during clinical support as a measure of feasibiity

Secondary outcome measures

36 items short form health survey

6 minute walk test

Disability assessment schedule

+10 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: CaRE-4-allBMT plus usual careExperimental Treatment1 Intervention

a longitudinal 6-month rehabilitation program that uses a person- centred strategy and a multidimensional approach targeting physical activity, nutrition, psychosocial distress and promoting self-management skills.

Group II: Usual care groupActive Control1 Intervention

No change to patient's usual care at Princess Margaret Cancer Centre.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CaRE-4-alloBMT plus usual care group

2021

N/A

~80

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,468 Previous Clinical Trials

484,410 Total Patients Enrolled

Jennifer M Jones, PhDPrincipal InvestigatorUniversity Health Network, Toronto

3 Previous Clinical Trials

761 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are partaking in this research?

"Affirmative. The clinicaltrials.gov database indicates that, since its original launch on September 8th 2021, this trial has been recruiting participants. 80 prospective patients are needed from a single location to fulfil the requirements of this experiment."

Answered by AI

What results are expected from this medical experiment?

"Over the course of 6 months, this clinical trial will be assessing drop-out rates as a measure for feasibility. Secondary objectives include charting healthcare utilization, gauging patient Body Mass Index (BMI), and tracking daily caloric intake with Fitbit devices."

Answered by AI

Are there any vacancies still available for this research program?

"Clinicaltrials.gov reflects that this study is open for recruitment, with the trial originally posted on 8th September 2021 and amended most recently on 14th November 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT

2021. "Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04966156.